Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$118.51 +1.2%	$106.36	$75.56 ▼ $139.13	$5.85B	0.51	611,443 shs	727,981 shs
NUVL Nuvalent	$76.08 +3.3%	$78.55	$55.53 ▼ $113.51	$5.49B	1.3	509,960 shs	407,091 shs
RNA Avidity Biosciences	$46.35 +3.8%	$35.63	$21.51 ▼ $56.00	$5.75B	0.95	3.90 million shs	1.89 million shs
SDGR Schrodinger	$20.32 +3.8%	$20.66	$16.60 ▼ $28.47	$1.44B	1.67	1.39 million shs	1.90 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.17%	+8.52%	+11.42%	+12.79%	+34.81%
NUVL Nuvalent	+3.30%	+0.05%	-5.47%	+3.52%	-7.96%
RNA Avidity Biosciences	+3.78%	-0.26%	+36.65%	+51.57%	+2.95%
SDGR Schrodinger	+3.78%	+4.85%	-11.77%	-5.05%	+1.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8015 of 5 stars	4.5	1.0	4.5	3.6	4.2	0.6
NUVL Nuvalent	3.4047 of 5 stars	4.5	1.0	0.0	3.3	3.3	0.0
RNA Avidity Biosciences	3.1733 of 5 stars	4.5	2.0	0.0	3.9	0.8	0.0
SDGR Schrodinger	3.0989 of 5 stars	3.3	3.0	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	50.20% Upside
NUVL Nuvalent	3.08	Buy	$118.91	56.29% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	44.55% Upside
SDGR Schrodinger	2.67	Moderate Buy	$27.83	36.98% Upside

Current Analyst Ratings Breakdown

Latest SDGR, RNA, AXSM, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/18/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $19.00
8/15/2025	SDGR Schrodinger	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00 ➝ $20.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	15.33	N/A	N/A	$1.46 per share	81.17
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.03 per share	N/A
RNA Avidity Biosciences	$10.90M	547.06	N/A	N/A	$9.27 per share	5.00
SDGR Schrodinger	$207.54M	7.21	N/A	N/A	$4.66 per share	4.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.02	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	11/11/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	11/11/2025 (Estimated)

Latest SDGR, RNA, AXSM, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
NUVL Nuvalent	N/A	13.57	13.57
RNA Avidity Biosciences	N/A	9.26	9.26
SDGR Schrodinger	N/A	3.30	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
NUVL Nuvalent	97.26%
RNA Avidity Biosciences	N/A
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
NUVL Nuvalent	10.20%
RNA Avidity Biosciences	3.83%
SDGR Schrodinger	21.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable
SDGR Schrodinger	790	73.61 million	58.15 million	Optionable

SDGR, RNA, AXSM, and NUVL Headlines

Recent News About These Companies

Schrödinger: A Complex Story With Many Moving Parts

August 21 at 12:27 PM | seekingalpha.com

Public Sector Pension Investment Board Raises Stake in Schrodinger, Inc. $SDGR

August 21 at 3:51 AM | marketbeat.com

Cetera Investment Advisers Takes Position in Schrodinger, Inc. $SDGR

August 21 at 3:08 AM | marketbeat.com

Morgan Stanley Cuts Schrodinger (NASDAQ:SDGR) Price Target to $19.00

August 20 at 10:33 AM | marketbeat.com

Morgan Stanley Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock Price

August 20 at 2:25 AM | americanbankingnews.com

What 4 Analyst Ratings Have To Say About Schrodinger

August 18, 2025 | benzinga.com

Tocqueville Asset Management L.P. Sells 23,590 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

August 18, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives $31.20 Consensus Price Target from Analysts

August 18, 2025 | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Shares Gap Down - Should You Sell?

August 17, 2025 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Upgraded to Strong-Buy at Barclays

August 17, 2025 | marketbeat.com

Tejara Capital Ltd Has $2.65 Million Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

August 17, 2025 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Shares Gap Down - Time to Sell?

August 17, 2025 | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Earns Overweight Rating from Analysts at Barclays

August 17, 2025 | americanbankingnews.com

Schrodinger (SDGR) Gets a Buy from Barclays

August 16, 2025 | theglobeandmail.com

Craig-Hallum Sticks to Its Buy Rating for Schrodinger (SDGR)

August 16, 2025 | theglobeandmail.com

Schrodinger (NASDAQ:SDGR) Sets New 12-Month Low - Here's What Happened

August 16, 2025 | marketbeat.com

Schrodinger downgraded at Citi after clinical program exit

August 16, 2025 | msn.com

Citigroup Downgrades Schrödinger (SDGR)

August 16, 2025 | msn.com

Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 16, 2025 | marketbeat.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | businesswire.com

Barclays Initiates Coverage of Schrödinger (SDGR) with Overweight Recommendation

August 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SDGR, RNA, AXSM, and NUVL Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$118.51 +1.37 (+1.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$118.47 -0.04 (-0.03%)

As of 08/22/2025 07:55 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Nuvalent NASDAQ:NUVL

$76.08 +2.43 (+3.30%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$76.08 0.00 (0.00%)

As of 08/22/2025 05:25 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$46.35 +1.69 (+3.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$46.45 +0.10 (+0.22%)

As of 08/22/2025 07:52 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$20.32 +0.74 (+3.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.95 -0.37 (-1.82%)

As of 08/22/2025 07:34 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time